I. Problems Nucleon is a small biotechnology start-up with a very promising potential product (CRP-1), which is also the first product that Nucleon is planning to go into the clinic market. Nucleon has reached to human clinical trials phase with its product and it has no manufacturing facilities that satisfy the guidelines for these clinical trials and testing. Nucleon is on the verge of making a critical choice of manufacturing strategy, which will affect Nucleon’s survival in the intense competition in the long haul. Nucleon management is aware of the facts that they have a limited budget to start with, the financial environment in biotechnology is rapidly changing and establishing the safety and efficacy of products like CRP-1 is complex, time-consuming and expensive; that’s why they want to evaluate risks and rewards of each manufacturing strategy before making their final decision. II. Alternatives Before moving on with clinical testing phase, Nucleon management is evaluating advantages and disadvantages for 3 main manufacturing strategies for the company. For Phase I and II these options are 1) building a new 5000-sq pilot plant supplying CRP-1 needed for Phases I and II, 2) contracting clinical manufacturing to an outside firm, and 3) licensing the manufacturing to another biotech or pharmaceutical firm. If CRP-1 succeeds in the first two phases, there are two more options available to the company for Phase III, that are 1) vertical integration to commercial marketing and 2) licensing manufacturing and marketing. III. Issues The main issue for Nucleon is the current capital availability. They only have $6.5 M at their hand when they are evaluating these options. Nucleon doesn’t have the option to going to pub... ... middle of paper ... ... come to nothing. Nucleon’s core competencies are doing proper scientific research with its team of experts and their strong link to academia leading to technical prowess; therefore, they should focus on the continuation of their expertise in science. If they choose not to license the product in the early stage and CRP-1 succeeds in Phase I & II, I recommend Nucleon to invest in a plant to supply the market on their own if they can find external support from investors. With their solid test result from Phases I & II I believe Nucleon can build trust in investors and get the initial investment. The expected return on this investment is very high compared to licensing the product at this phase. However if they don’t end up finding external support, they can still license the product at Phase III and enjoy the immediate cash flow followed by the royalty payments.
Faboil Ltd has evolved into a relatively successful organisation in the biotechnology field. The success of the company and its paternal approach was adopted by Dr Alfred Brownlow. Dr Brownlow has led from the front in terms of developing the product range for Faboil Ltd. Richard Cranberry (Director of Biotechnology) has driven very hard to maintain the success of the company, although the organisation lag behind in terms of modus operandi technology. At present, the monopoly position of Faboil Ltd has slowly eroded away and faces two competitors. The major causes are that the new products have failed to live up to market expectations and it is at a backward stage only holding a 20% market share. This report will find the causes of issues in the company and give ideas and resolutions on how to fix the problem.
Pseudobulbar Affect (PBA) is a neurological condition that causes the patient to experience inappropriate and uncontrollable laughing and crying, which is an exaggeration of the emotions experienced or, in some instances, totally unrelated to the patient’s emotions. Episodes, which can last from seconds to several minutes, are often mistaken for mood disorders and can be disruptive to daily living (Mayo, 2017). Approximately 43 to 49 percent of ALS patients suffer from PBA (BCM, 2017).
Research and development is a very important aspect of this industry and it is very draining on a company's funds. Great emphasis is also placed on product placement and marketing. Though these products are usually marketed towards industry professionals such as doctors and hospital management.
1. Elon is located in the state of North Carolina in the Piedmont Triad area, 20 minutes east of Greensboro and 30 minutes north- west of Durham and Chapel Hill and the address of the school is 100 Campus Drive, Elon, NC 27244.
Custom Chip, Inc case describes the situation of a company where lack of coordination and cooperation among different departments is hindering them to achieve their common or ultimate goal as a single business entity. Applications engineering, product engineering and manufacturing are all inclined towards achieving their individual objectives and timelines rather than collaborating and synergizing their efforts in order to attain a common goal of effective production with improved cost reduction. Few of the primary reasons are insufficient and unorganized company policies for coordination and cooperation, poor networking with in the organization especially on management level, lack of communication and influence among managers and VPs, insufficient human resource, and measuring a department's effectiveness solely on its performance based on individual objectives, rather than checking its effects on over all company's performance.
Nuclear waste has a reputation for making law makers and the public uneasy, thus it is difficult to find a site for nuclear waste disposal units. However, creating such sites is necessary to allow nuclear energy to the electricity production forefront in America. In the search for a waste disposal location, companies have been turning toward Native American reservations as the final resting places of the radioactive waste. Multiple tribes have quickly denied companies access to their land, but others have taken advantage of the potentially prosperous opportunity. One of the first tribes to decline a waste site was the Navajos, for the nuclear industry’s destruction of their land was still fresh in their minds. It is true that nuclear waste disposal is a theoretically dangerous venture, yet it also contains many potential benefits. Siting a nuclear waste unit on the Navajo reservation would benefit the country and the Navajos, but the idea is meet with reluctance because of the suspected costs to the Navajo people, the environment as a whole, and the Navajo’s land.
Over the past decade, scientists have made significant advancements in the treatment of certain diseases. Unfortunately, just like any new product, the cost of developing these new technologies and treatments is extremely high. Plus, unlike other technology, heath technolo...
"Public Acceptance Of Nuclear -- How Can It Be Fixed?." Mechanical Engineering 135.6 (2013): 53-54. Business Source Elite. Web. 6 Dec. 2013.
trials of investigation medical products. The FDA also has to review and approve in a
biopharmaceutical industry. Manuscript submitted for publication, Sloan School of Management and the Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts. Retrieved from dspace.mit.edu/bitstream/handle/1721.1/34827/61670866.pdf?sequence=1.
"Dangers of Molecular Manufacturing." An Overview of CRN's Current Findings . Center for Responsible Nanotechnology, 2008. Web. 13 Jul 2011. .
... high energy density method, but also while being environmentally healthy as well as sustainable for years to come. In comparison to any other nuclear resource, nuclear energy is the solution that is reliable and powerful. Although interpreted as being affiliated with nuclear warfare, it is in fact, streamlined for an energy model. Hard limits that are put in place by uranium deficiencies and excessive nuclear waste are built on false data. Uranium, being a relatively common metal, can be easily accessible. Nuclear waste disposal is not only safe, but is also being reduced every day. By being used in medicine and space missions as well as minimizing emissions, nuclear energy is also a means to a better environment as well as innovation. Only with nuclear energy, can global energy demands be met and the world can be ushered into a cleaner and more innovative future.
... product will work out (Kaiser, Jocelyn. Science). These different methods are starting to pave a way for companies to stop using animals in experiments in the near future.
Furthermore, the future of this industry has a definite growth forthcoming. As we approach fusion power as a reality, nuclear engineers will be essential components to the distribution of a clean, safe energy source.
...nuing to profit from the substaining usage of animals in scientific laboratories, the tradtional method is difficult to dispose of. The method is kept for the currency but fails to produce major reliable success as those of the alternative methods. A statisict shown in Safer Medicines Trust states, "that nindy-two percent of drugs fail in clinical trials, having successfully passed through animal studies." These corportaions care more about the amount of money profited than the reliablitily of the results from animal testing.